Study finds new psoriasis treatment tops competition
A recent study suggests that the biologic medication may ustekinumab reduce psoriasis symptoms better than Enbrel, and with fewer doses. The late-stage study of 900 patients found that ustekinumab reduced psoriasis patches in two thirds of the patients, while Enbrel appeared to reduce patches in half of the patients. Drugmaker Johnson & Johnson has applied for U.S. Food and Drug Administration approval for ustekinumab and report that they expect a decision on the medication this year.
Read full story >
See all Skin Care News
People who read this also read...
What the community is saying...
Olive Oil Not Just for Cooking
Posted 11/20 Comments (0)
For centuries the people of the Mediterranean have recognized the benefits of olive oil to nourish and moisturize the skin......
